Aignostics

One-liner: “Aignostics develops AI solutions for the biopharma industry, focusing on drug development and precision medicine.”

Company slogan: AI-powered precision diagnostics for pathology

Positioning: “Aignostics positions itself as a provider of advanced AI solutions specifically tailored for the biomedical sector, focusing on drug development and precision medicine.”

Description: “Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.”

Employees: 118

Website: Visit website

Headquarters: “Berlin, Berlin”

Ownership: Privately Held

Founded: 2018

Company type: AI company

Use cases: “drug development, precision medicine, translational research, clinical trials, companion diagnostics”

Pricing: –

Client sector: biopharma

Business model: subscription

Products: “RudolfV, foundation model for histopathology”

Is API available: no

Website title: Aignostics – Turning complex biomedical data into transformative insights

Website description: none

Linkedin: https://www.linkedin.com/company/aignostics

Youtube: –

Instagram: –

Facebook: –

Twitter: https://twitter.com/aignostics

Crunchbase: https://www.crunchbase.com/organization/aignostics

Email: –